FTC Accuses Endo Pharmaceuticals Of "Pay-For-Delay" Agreements; Analysts Not WorriedMani
The Federal Trade Commission said Thursday that Endo Pharmaceuticals violated federal antitrust laws by paying Impax Laboratories and Watson Laboratories to delay launching their approved generic versions. The latest case is the first by the commission that challenges an agreement not to market an authorized generic.
FTC claims "pay-for-delay" agreements cost consumers billions
exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible